PACIFICO logo

PACIFICO

Purine-Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC lite

PACIFICO

Purine-Alkylator Combination In Follicular lymphoma Immuno-Chemotherapy for Older patients: a phase III comparison of first-line R-CVP versus R-FC lite
Funding CRUK & ROCHE
Portfolio Cancer
Interventions Medicine
Randomised Yes
Status In Follow-up
Start Date 09-Sep-2009

Follicular lymphoma (FL) is the most frequently occurring type of indolent non-Hodgkin's lymphoma (NHL) in developed countries. The annual incidence is highest in patients aged 60 or over (1). The disease is usually widespread at presentation and is not curable with currently available treatments. The clinical course is one of recurrent remissions and relapses, the median survival being approximately 10 years from diagnosis

In the UK, R-CVP is approved by NICE for the first-line treatment of FL and is consequently regarded as the standard induction regimen for patients of all ages.

Older patients are almost certainly under-represented in clinical trials of FL owing to a trend for treatment regimens to become ever more intensive and because of the increasing stringency of inclusion criteria. Consequently, there is a lack of data concerning the optimal R-chemotherapy induction regimen in this patient group. The present study aims to remedy this situation by targeting patients with FL aged 60 or over.

Publications

  • N/A